Rinri Therapeutics is developing a novel stem cell-based therapy aimed at restoring hearing by reversing sensorineural hearing loss (SNHL). Its technology seeks to repair the damaged cytoarchitecture in the inner ear using auditory stem cells. The approach is based on research led by Professor Marcelo Rivolta at the University of Sheffield, and the company was spun out from that institution. Rinri is led by Dr Simon Chandler, CEO, and is based in Sheffield, England. It raised a total of £10m in funding from investors including Boehringer Ingelheim Venture Fund, UCB Ventures, BioCity and the UK Government Future Fund to support development of the therapy. The program targets an area with no current pharmacological treatment options for SNHL patients, reflecting a significant unmet medical need. Rinri Therapeutics is developing advanced stem cell–based therapeutics aimed at restoring hearing. Its lead technology seeks to reverse neuropathic sensorineural hearing loss by repairing damaged cytoarchitecture in the inner ear. The company is a spin‑out of Sheffield University and its work builds on the research of Professor Marcelo Rivolta (Chen et al., 2012, Nature). Founded in late‑2018 and led by CEO Dr Simon Chandler, Rinri is based in Sheffield, England, UK. It secured £1.4m in seed funding and intends to use the proceeds for ongoing growth. Investor representatives have joined the board to support the company’s development and commercialization efforts.

Total raised

$16M

Funding rounds

2

Latest round

Equity

Latest activity

Apr 2021